Compounded Semaglutide Is Going Away — Here's What to Do Now

The FDA ended the drug shortage — and with it, your access to cheap compounded semaglutide. Here's what patients need to know and where to find legal alternatives.

What Just Changed

For nearly two years, semaglutide and tirzepatide seemed almost accessible. Compounding pharmacies across the country filled prescriptions for these weight-loss drugs at a fraction of brand-name prices — $150 to $300 per month instead of $900 to $1,300. But that window is officially closing.

In February 2025, the FDA removed semaglutide from its national shortage list, determining that the current supply can meet present and future demand. Six months earlier, in October 2024, tirzepatide (Zepbound/Mounjaro) had already been removed. What sounds like good news — "the shortage is over!" — has a serious downside: compounding pharmacies can no longer legally manufacture these drugs.

The rule is clear. Once a shortage ends, compounding pharmacies cannot legally make drugs that are "essentially a copy" of an FDA-approved medication. Semaglutide injections are now off-limits. Tirzepatide is off-limits. Any compounded version identical or nearly identical to Wegovy, Ozempic, Zepbound, or Mounjaro violates federal law.

For millions of patients who found their only affordable entry point through compounded GLP-1s, this change means one of three things: paying exponentially more, finding alternatives, or losing access entirely.

The Timeline and What's at Stake

The transition dates matter. According to FDA guidance, 503A compounding pharmacies (state-regulated compounders) could continue manufacturing semaglutide until April 22, 2025. 503B outsourcing facilities (larger compounders) had until May 22, 2025. Those deadlines have now passed. Any clinic, pharmacy, or telehealth provider still offering "compounded semaglutide 2026" is operating in a legal gray zone.

And enforcement is real. The FDA has signaled aggressive priorities: targeting compounding without documented medical necessity, unlicensed manufacturing, misleading marketing (claiming compounded drugs are "equivalent" to approved versions), and the use of research-grade ingredients not intended for human use. The agency has not banned all compounding outright, but it has made clear that mass-marketed copycat versions are prohibited.

Drug manufacturers have escalated enforcement further. Novo Nordisk and Eli Lilly have issued cease-and-desist letters to compounding pharmacies, weight-loss clinics, and even prescribing physicians. The Department of Justice has even investigated some telehealth platforms offering these products. This is not a gray area anymore — it's becoming a liability.

For patients, the stakes are personal. Thousands relied on compounded GLP-1s as their only option. A sudden loss of supply means either an abrupt gap in treatment or a dramatic price jump. Neither is safe or sustainable.

The Brand-Name Reality Check

Here's where the math gets hard. Brand-name Ozempic and Wegovy (semaglutide) now cost $299 to $349 per month for ongoing fills — when you pay cash. Novo Nordisk has offered some temporary relief with an introductory price of $199 per fill for eligible new patients, but that expires March 31, 2026. After that, the price returns to standard rates: roughly $900 to $1,300 per month out-of-pocket.

Zepbound (tirzepatide), the newer and slightly more effective option, carries similar pricing. Insurance can help — Medicaid now covers GLP-1 injectables at no cost, and Medicare beneficiaries pay a maximum $50 per month copay. But for uninsured or underinsured patients, the gap between what they were paying ($150–$300) and what they'll pay now ($900+) is staggering.

Some cheaper alternatives do exist. Liraglutide (the active ingredient in Victoza and Saxenda) now has an authorized generic version, making it the least expensive FDA-approved GLP-1 on the market for many out-of-pocket payers. Other diabetes-approved GLP-1s like Mounjaro, Trulicity, and Bydureon may also be options, depending on your health profile and insurance. But none of these are as potent as semaglutide or tirzepatide for weight loss.

Coming Generics — But Not Soon Enough

There is hope on the horizon. Patent expirations for semaglutide and tirzepatide are approaching in the coming years, which means true generic versions should eventually flood the market at a fraction of current prices. But "eventually" could be 2027, 2028, or later. For patients who need help with weight management now, waiting is not a realistic option.

This gap — between the collapse of compounding access and the arrival of affordable generics — is creating a crisis for budget-conscious patients. They're stuck between an illegal, risky path (unlicensed compounding) and an unaffordable one (brand names).

How GlowRoute Helps You Navigate This Shift

This is where clarity matters. GlowRoute exists to connect patients with licensed, medically supervised weight-loss clinics that offer legal, compliant GLP-1 programs. We don't carry compounded drugs. We don't cut legal corners. Instead, we help you find clinics near you that:

• Prescribe FDA-approved semaglutide, tirzepatide, or alternatives through legitimate channels
• Use licensed pharmacies and proper supply chains
• Offer medical supervision and ongoing monitoring (which is crucial for GLP-1 safety)
• Often have pricing models, payment plans, or membership programs that work around the $900 sticker shock
• Are transparent about costs upfront, so you know what you're paying before you commit

Many compliant clinics operate on direct-pay or membership models that are significantly cheaper than brand-name pharmacy prices. Others work with wholesalers or have sourcing strategies that reduce costs. A growing number of employers and insurance plans are also covering GLP-1 treatment at reasonable copays.

The key insight: legality and affordability are not mutually exclusive. You don't have to choose between breaking the law and going broke. Licensed clinics exist in a middle ground — and GlowRoute makes finding them simple.

What This Means for You

If you were using compounded semaglutide or tirzepatide: Your current supply is drying up or already gone. Don't wait for your pharmacy to close the door. Start now by talking to your prescriber about what comes next. Whether that's a brand-name drug, a generic alternative, or a different GLP-1 entirely, a plan is better than a panic.

If you're considering GLP-1 treatment: The compounded route is no longer a shortcut. But that doesn't mean it's unaffordable. Legal GLP-1 clinics have emerged with models designed for real patients with real budgets. Shop around. Ask about memberships, tiered pricing, or payment plans. Some clinics charge $200 to $400 per month all-in — less than you might expect.

If you're worried about cost: You're not alone. The GLP-1 affordability crisis is real, and it's why GlowRoute exists. We help you find clinics near you that balance quality with cost. No guesswork. No hidden fees. Just verified, licensed clinics ready to support your weight-loss goals.

---

The window for compounded semaglutide has closed. But your options haven't. Find a licensed GLP-1 weight-loss clinic near you today at GlowRoute^[1]. Get connected to medical supervision, FDA-approved medications, and transparent pricing — all in your area.

---

Sources

• FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize^[2]
• The FDA Removes Semaglutide from the Drug Shortage List | Burr & Forman LLP^[3]
• FDA Ends Semaglutide Shortage Listing, Contributing to Ongoing Legal Challenges | Pharmacy Times^[4]
• Semaglutide shortage is over, FDA says; grants discretion for compounding pharmacies | NCPA^[5]
• FDA Announces End to Semaglutide Shortage, Impacting Compounders and Telehealth Providers Offering Injectable GLP-1 Drugs | ArentFox Schiff^[6]
• Comparing Ozempic, Wegovy and Other GLP-1 Drugs - GoodRx^[7]
• GLP-1 Drug Savings: A Complete Guide for How to Save on Ozempic, Wegovy, and More - GoodRx^[8]